Bristol-Myers Squibb, playing catch-up in hepatitis C, picked up FDA approval for a virus-blocking agent to be used in tandem with Sovaldi, Gilead Sciences' blockbuster success.
Here's an earnings trend-buster: Bristol-Myers Squibb trounced expectations for the second quarter and hiked its full-year sales forecast by more than $1 billion.
Bristol-Myers Squibb nabbed a "breakthrough" tag from the FDA for its next-gen HIV therapy aimed at patients who become resistant to the drugs now in use.
Bristol-Myers Squibb has nabbed a breakthrough therapeutic designation for a next-gen HIV therapy aimed at offering an option for patients who become resistant to the therapies now in use.
Bristol-Myers Squibb can brag about another success with immunotherapy Opdivo. A late-stage study in advanced kidney cancer will be stopped early, after a monitoring committee flagged improved survival results for Opdivo, compared with the Novartis treatment Afinitor.
Bristol-Myers Squibb hit a big milestone in its quest to expand use of the immunotherapy Opdivo in a slate of cancer types. In a late-stage kidney cancer study, Opdivo showed a survival advantage over Novartis' Afinitor, prompting a monitoring committee to stop the trial early.
Bristol-Myers Squibb flagged an early success for its Phase III Opdivo (nivolumab) study for kidney cancer, saying that an independent monitoring group concluded that its closely watched checkpoint inhibitor has beat Afinitor (everolimus) in improving overall survival for advanced patients.
Pharma-watchers may be very familiar with immuno-oncology. But the average American doesn't necessarily know what the term means--or why it's important. Bring on "Modern Family" star Eric Stonestreet.
Bristol-Myers Squibb is teaming up with researchers at the Medical University of South Carolina to shed some light on the root causes of fibrotic disease, planning translational studies on a handful of ailments with hopes of spotlighting new treatments.
The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.